NASDAQ:LOXO - Loxo Oncology Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$234.66
+0 (0.00%)
Get New Loxo Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LOXO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LOXO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Loxo Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $234.66.

This chart shows the closing price for LOXO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Loxo Oncology. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2019William BlairDowngradeOutperform ➝ Market PerformLow
1/8/2019CitigroupDowngradeBuy ➝ NeutralLow
1/7/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
1/7/2019Ifs SecuritiesDowngradeOutperform ➝ Market PerformLow
1/7/2019William BlairReiterated RatingBuyHigh
12/21/2018OppenheimerInitiated CoverageBuy$185.00Medium
11/29/2018JMP SecuritiesReiterated RatingBuy$215.00High
11/28/2018CitigroupBoost Price TargetBuy$201.00Medium
11/27/2018William BlairReiterated RatingBuyLow
11/27/2018Piper Jaffray CompaniesSet Price TargetBuy$200.00High
11/16/2018CitigroupLower Price TargetBuy ➝ Buy$233.00 ➝ $213.00Medium
11/14/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$235.00High
11/13/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Buy$221.00 ➝ $215.00Medium
10/24/2018CitigroupLower Price TargetBuy ➝ Buy$235.00 ➝ $233.00High
10/22/2018Piper Jaffray CompaniesSet Price TargetBuy$200.00Medium
10/22/2018William BlairReiterated RatingBuyMedium
10/22/2018CowenReiterated RatingBuyMedium
10/11/2018Morgan StanleyLower Price TargetOverweight$215.00 ➝ $213.00High
10/8/2018Ifs SecuritiesUpgradeMarket Perform ➝ OutperformMedium
10/8/2018William BlairReiterated RatingBuyMedium
10/7/2018Piper Jaffray CompaniesSet Price TargetBuy$200.00Medium
10/7/2018CowenReiterated RatingBuyMedium
9/26/2018Piper Jaffray CompaniesSet Price TargetBuy$200.00High
9/24/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$205.00Medium
9/17/2018GuggenheimInitiated CoverageNeutralMedium
9/17/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$165.00High
8/10/2018Stifel NicolausLower Price TargetBuy$225.00 ➝ $217.00High
8/9/2018CowenReiterated RatingBuyHigh
6/4/2018Ifs SecuritiesDowngradeStrong-Buy ➝ Market PerformLow
6/4/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Buy$182.00 ➝ $221.00High
6/4/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$170.00 ➝ $200.00High
6/4/2018CitigroupBoost Price TargetBuy$235.00High
6/4/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$190.00 ➝ $225.00High
6/4/2018William BlairReiterated RatingBuyHigh
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweight$200.00Medium
5/18/2018CitigroupBoost Price TargetBuy$178.00Low
5/17/2018JMP SecuritiesSet Price TargetBuy$152.00 ➝ $182.00Medium
5/17/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$145.00 ➝ $190.00High
5/17/2018BTIG ResearchReiterated RatingBuy$156.00High
5/9/2018JMP SecuritiesSet Price TargetBuy$95.00 ➝ $152.00High
5/9/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$135.00 ➝ $145.00High
4/16/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$130.00 ➝ $170.00High
4/16/2018William BlairReiterated RatingBuyHigh
3/21/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$103.00High
3/5/2018CitigroupReiterated RatingBuy ➝ Buy$108.00 ➝ $151.00High
3/2/2018Stifel NicolausReiterated RatingBuy$135.00High
2/22/2018CIBCInitiated CoverageOutperform ➝ Outperform$132.00Low
2/22/2018OppenheimerInitiated CoverageOutperform$132.00Low
11/28/2017William BlairInitiated CoverageOutperformHigh
11/16/2017CitigroupLower Price TargetBuy$112.00 ➝ $108.00N/A
11/14/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$77.18 ➝ $95.00N/A
11/14/2017Ifs SecuritiesUpgradeOutperform ➝ Strong-BuyN/A
10/20/2017CitigroupReiterated RatingBuy$86.00 ➝ $112.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$95.00 ➝ $103.00N/A
9/29/2017BTIG ResearchReiterated RatingBuy$75.00 ➝ $102.00Low
9/28/2017CowenReiterated RatingBuyLow
8/29/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
8/10/2017Stifel NicolausReiterated RatingBuy$71.00 ➝ $94.00High
8/8/2017Ifs SecuritiesReiterated RatingOutperformLow
8/3/2017Stifel NicolausReiterated RatingBuy$71.00Low
8/3/2017BTIG ResearchReiterated RatingBuy$75.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

-0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Loxo Oncology logo
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.
Read More

Today's Range

Now: $234.66
Low: $234.66
High: $234.66

50 Day Range

MA: N/A

52 Week Range

Now: $234.66
Low: $101.70
High: $234.93

Volume

400 shs

Average Volume

565,561 shs

Market Capitalization

$7.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Loxo Oncology?

The following equities research analysts have issued research reports on Loxo Oncology in the last twelve months:
View the latest analyst ratings for LOXO.

What is the current price target for Loxo Oncology?

0 Wall Street analysts have set twelve-month price targets for Loxo Oncology in the last year.
View the latest price targets for LOXO.

What is the current consensus analyst rating for Loxo Oncology?

Loxo Oncology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for LOXO.

How do I contact Loxo Oncology's investor relations team?

Loxo Oncology's physical mailing address is 281 TRESSER BOULEVARD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company's listed phone number is 203-653-3880 and its investor relations email address is [email protected] The official website for Loxo Oncology is www.loxooncology.com. Learn More about contacing Loxo Oncology investor relations.